Clinical Trial Update: 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating 68Ga-DOTA-MGS5 PET/CT imaging in patients with advanced neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• 68Ga-DOTA-MGS5 (68Ga-DOTA-MGS5)

Snippet

Sponsor: Medical University Innsbruck | Conditions: Neuroendocrine Tumors | Phase 1, Phase 2 | Status: COMPLETED